{"document_type": "article", "byline": {"person": [{"role": "reported", "firstname": "Katie", "organization": "", "rank": 1, "lastname": "THOMAS"}], "original": "By KATIE THOMAS"}, "news_desk": "Business", "slideshow_credits": null, "abstract": "Valeant Pharmaceuticals says it is being investigated by Securities and Exchange Commission; has come under scrutiny for its high drug prices and dealings with mail-order pharmacy.", "multimedia": [{"type": "image", "url": "images/2016/03/01/business/01VALEANTSUPERREFER/01VALEANTSUPERREFER-thumbWide.jpg", "legacy": {"wide": "images/2016/03/01/business/01VALEANTSUPERREFER/01VALEANTSUPERREFER-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "width": 190, "subtype": "wide", "height": 126}, {"type": "image", "url": "images/2016/03/01/business/01VALEANTSUPERREFER/01VALEANTSUPERREFER-articleLarge.jpg", "legacy": {"xlarge": "images/2016/03/01/business/01VALEANTSUPERREFER/01VALEANTSUPERREFER-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "400"}, "width": 600, "subtype": "xlarge", "height": 400}, {"type": "image", "url": "images/2016/03/01/business/01VALEANTSUPERREFER/01VALEANTSUPERREFER-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/03/01/business/01VALEANTSUPERREFER/01VALEANTSUPERREFER-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "width": 75, "subtype": "thumbnail", "height": 75}], "headline": {"print_headline": "<span data-tag=\"tight__4\">After Tumultuous Day for Valeant, Latest Blow Is an S.E.C. Investigation</span>", "main": "Valeant Pharmaceuticals Is Under S.E.C. Investigation"}, "print_page": "3", "keywords": [{"value": "Drugs (Pharmaceuticals)", "is_major": "Y", "rank": "1", "name": "subject"}, {"value": "Valeant Pharmaceuticals International Inc", "is_major": "Y", "rank": "2", "name": "organizations"}, {"value": "Securities and Exchange Commission", "is_major": "Y", "rank": "3", "name": "organizations"}, {"value": "Pearson, John Michael (1959- )", "is_major": "N", "rank": "4", "name": "persons"}], "snippet": "The beleaguered drug maker, already under scrutiny for its steep price increases, earlier canceled its fourth-quarter earnings report.", "source": "The New York Times", "lead_paragraph": "The beleaguered drug maker, already under scrutiny for its steep price increases, earlier canceled its fourth-quarter earnings report.", "word_count": "641", "pub_date": "2016-03-01T00:00:00Z", "subsection_name": null, "blog": [], "type_of_material": "News", "section_name": "Business Day", "web_url": "http://www.nytimes.com/2016/03/01/business/valeant-pharmaceuticals-is-under-sec-investigation.html", "_id": "56d4c6f438f0d811294b816c"}